CClinicalTrials.gg
CompletedNCT03023475Updated Feb 25, 2020

Comparison of Two Different Endoscopic Radial Artery Harvesting Devices

An interventional study of LigaSure endoscopic vessel harvesting and TLS2 endoscopic vessel harvesting in CABG Graft Integrity, sponsored by Kerckhoff Klinik. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-25.

Sponsored by Kerckhoff Klinik · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Endoscopic radial artery harvesting in coronary bypass surgery is routinely performed by the investigators. In this study, the investigators want to compare the MiFusion TLS2 (Endotrust GmbH, Germany) device to the LigaSure Maryland Jaw (Medtronic, USA). The vessel harvesting is performed in the standard fashion according to the institutional routine. The patients are randomized preoperatively to one of the devices. The proximal end of the radial artery will be preserved and deep-frozen for histological assessment. Endothelial integrity will be investigated using Hematoxylin-Eosin, CD31 and endothelial nitrogen monoxide synthase.

02

Conditions studied

  • CABG Graft Integrity
03

In context

Lead sponsor

Kerckhoff Klinik is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • all adult patients undergoing CABG using the radial artery
  • capability to give informed consent

Exclusion criteria

Exclusion Criteria:

  • no specific exclusion criteria
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Active comparator
    LigaSure endoscopic radial harvesting

    The endoscopic vessel harvesting will be performed using the LigaSure device.

    Device: LigaSure endoscopic vessel harvesting

  • Active comparator
    TLS2 endoscopic radial harvesting

    The endoscopic vessel harvesting will be performed using the TLS2 device.

    Device: TLS2 endoscopic vessel harvesting

Interventions

  • DeviceLigaSure endoscopic vessel harvesting

    The radial artery will be harvested endoscopically using the LigaSure system.

  • DeviceTLS2 endoscopic vessel harvesting

    The radial artery will be harvested endoscopically using the TLS2 system.

06

What researchers measure

Primary outcomes

  1. Endothelial integrity of the radial artery using histological examination.

    Time frame: Through study completion, an average of 1 year.

Secondary outcomes

  1. Harvesting time

    Time frame: The harvesting time will be measured during the vessel harvesting surgery.

  2. Hemostasis in the arm indicated by bleeding from radial artery side branches or veins in the arm.

    Time frame: Intraoperatively and directly after vessel harvesting the arm is controlled using the endoscope and bleeding can be detected during this control. End of surgery is end of this outcome parameter.

  3. Accuracy of vessel sealing, if side branches of the radial artery are bleeding after blood insufflation, additional clips have to placed at the side branch.

    Time frame: The blood insufflation is performed immediately after vessel harvesting and leaks can be detected.

07

Study locations

1 site
  • Kerckhoff Klinik
    Bad Nauheim, 61231, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03023475
Lead sponsor
Kerckhoff Klinik
Responsible party
Sponsor
First posted
Jan 18, 2017
Start date
Feb 1, 2017
Primary completion
Sep 30, 2017
Completion
Feb 28, 2018
Last update
Feb 25, 2020

Study contacts

Arnaud Van Linden, MD
principal investigator · Kerckhoff Klinik

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion